特别针对印度人口的血脂临床试验。

IF 1.4 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Indian heart journal Pub Date : 2024-03-01 DOI:10.1016/j.ihj.2024.02.003

Aseem Basha, Sivasubramanian Ramakrishnan

{"title":"特别针对印度人口的血脂临床试验。","authors":"Aseem Basha, Sivasubramanian Ramakrishnan","doi":"10.1016/j.ihj.2024.02.003","DOIUrl":null,"url":null,"abstract":"<div><p>Indians have a pattern of atherogenic dyslipidaemia characterised by not so high LDL-C but elevated small, dense LDL-C, elevated triglyceride levels and low HDL-C levels. In addition, different lipid-lowering drugs exhibit pharmacokinetic variability in Indians, which may have implications on the optimum doses required to achieve the desired LDL-C levels. Currently the management of dyslipidaemia in Indians are based on the landmark trials, which largely included western population. This review focusses on major clinical trials of lipid lowering drugs with special reference to the Indian population.</p></div>","PeriodicalId":13384,"journal":{"name":"Indian heart journal","volume":"76 ","pages":"Pages S130-S137"},"PeriodicalIF":1.4000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S001948322400021X/pdfft?md5=6874da94edf8821c5ba8703eb9de9adb&pid=1-s2.0-S001948322400021X-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Lipid clinical trials with special reference to Indian population\",\"authors\":\"Aseem Basha, Sivasubramanian Ramakrishnan\",\"doi\":\"10.1016/j.ihj.2024.02.003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Indians have a pattern of atherogenic dyslipidaemia characterised by not so high LDL-C but elevated small, dense LDL-C, elevated triglyceride levels and low HDL-C levels. In addition, different lipid-lowering drugs exhibit pharmacokinetic variability in Indians, which may have implications on the optimum doses required to achieve the desired LDL-C levels. Currently the management of dyslipidaemia in Indians are based on the landmark trials, which largely included western population. This review focusses on major clinical trials of lipid lowering drugs with special reference to the Indian population.</p></div>\",\"PeriodicalId\":13384,\"journal\":{\"name\":\"Indian heart journal\",\"volume\":\"76 \",\"pages\":\"Pages S130-S137\"},\"PeriodicalIF\":1.4000,\"publicationDate\":\"2024-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S001948322400021X/pdfft?md5=6874da94edf8821c5ba8703eb9de9adb&pid=1-s2.0-S001948322400021X-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Indian heart journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S001948322400021X\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian heart journal","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S001948322400021X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

摘要

印度人的动脉粥样硬化性血脂异常的特点是低密度脂蛋白胆固醇（LDL-C）并不高，但小而密集的低密度脂蛋白胆固醇（LDL-C）升高，甘油三酯水平升高，而高密度脂蛋白胆固醇（HDL-C）水平较低。此外，不同的降脂药物在印度人体内的药代动力学存在差异，这可能会影响到达到理想 LDL-C 水平所需的最佳剂量。目前，对印度人血脂异常的管理主要基于里程碑式的试验，这些试验主要包括西方人群。本综述重点介绍降脂药物的主要临床试验，并特别关注印度人群。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Lipid clinical trials with special reference to Indian population

Indians have a pattern of atherogenic dyslipidaemia characterised by not so high LDL-C but elevated small, dense LDL-C, elevated triglyceride levels and low HDL-C levels. In addition, different lipid-lowering drugs exhibit pharmacokinetic variability in Indians, which may have implications on the optimum doses required to achieve the desired LDL-C levels. Currently the management of dyslipidaemia in Indians are based on the landmark trials, which largely included western population. This review focusses on major clinical trials of lipid lowering drugs with special reference to the Indian population.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Indian heart journal CARDIAC & CARDIOVASCULAR SYSTEMS-

CiteScore

2.60

自引率

6.70%

发文量

审稿时长

52 days

期刊介绍： Indian Heart Journal (IHJ) is the official peer-reviewed open access journal of Cardiological Society of India and accepts articles for publication from across the globe. The journal aims to promote high quality research and serve as a platform for dissemination of scientific information in cardiology with particular focus on South Asia. The journal aims to publish cutting edge research in the field of clinical as well as non-clinical cardiology - including cardiovascular medicine and surgery. Some of the topics covered are Heart Failure, Coronary Artery Disease, Hypertension, Interventional Cardiology, Cardiac Surgery, Valvular Heart Disease, Pulmonary Hypertension and Infective Endocarditis. IHJ open access invites original research articles, research briefs, perspective, case reports, case vignette, cardiovascular images, cardiovascular graphics, research letters, correspondence, reader forum, and interesting photographs, for publication. IHJ open access also publishes theme-based special issues and abstracts of papers presented at the annual conference of the Cardiological Society of India.